At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
Radium-223 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Jul 30, 2019·Updated Dec 19, 2025
In Brief
A Phase 2 clinical trial evaluating Radium-223 and stereotactic ablative radiotherapy (SABR) for Prostate Cancer. Completed, enrolled 64 participants across 1 site.
Detailed Summary
This is a Phase II non-blinded randomized study evaluating men with oligometastatic prostate cancer lesions randomized (1:1) to stereotactic ablative radiation therapy (SABR) versus SBAR + Radium-223. We are looking to determine the progression-free survival of men who have oligometastatic prostate cancer with at least one bone metastasis with stereotactic ablative radiation therapy (SABR) versus SABR + Radium-223.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsCongressionally Directed Medical Research Programs, Bayer
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartAug 2019
Primary CompletionJul 2025
TodayJul 2026
First PostedJul 30, 2019
Enrollment StartAug 9, 2019
Primary CompletionJul 15, 2025
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 6.9 years ago
Interventions
Radium-223drug
Radium-223 plus SABR will be within two weeks.
stereotactic ablative radiotherapy (SABR)radiation
SABR 1-5 fractions